|
MechanismKRAS G12V inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismMAGEA3 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ RecruitingEarly Phase 1IIT To Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of T Cell Receptor T Cell Therapy in the Treatment of Advanced Pancreatic Cancer
To investigate the safety, tolerability, efficacy and pharmacokinetics of TCR-T cells in the treatment of advanced pancreatic cancer
100 Clinical Results associated with Shanghai Essight Bio Co.,Ltd
0 Patents (Medical) associated with Shanghai Essight Bio Co.,Ltd
100 Deals associated with Shanghai Essight Bio Co.,Ltd
100 Translational Medicine associated with Shanghai Essight Bio Co.,Ltd